RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans.

Albendazole is a benzimidazole derivative with proven efficacy against many parasites such as intestinal helminths. Toxocariasis is one of the important parasitic diseases in humans and animals caused by Toxocara canis. It is well known that T. canis larvae migrate in paratenic hosts, including humans where it may cause visceral larva migrans. Thus, the present research was carried out using in vivo experiments with the aim of finding whether novel albendazole microparticles would be active against migrating larvae of the parasite. Albendazole-chitosan microparticles were prepared by ionotropic gelation with sodium lauryl sulphate or by a liquid-liquid phase separation with sodium hydroxide. Mice were infected with T. canis and then treated with both albendazole-chitosan microparticles. After treatment (28days post-infection), it was examined the anthelmintic effect in mice after oral administration of microparticulate preparations. The number of larvae recovered from mice treated with albendazole formulations were compared with placebo. The results showed that albendazole microparticles were easily prepared in high yield using both aqueous solutions of sodium lauryl sulphate or sodium hydroxide. In vivo evaluation of larva migration showed that albendazole microparticles exhibited a greater anthelmintic effect in the brain (0 larva/mouse). In addition, it was also found that liver and lung showed a significant decrease in the number of larvae. Therefore, these data suggest that albendazole-chitosan microparticles are effective formulations for the treatment of toxocariasis infection by reducing the number of larvae in liver and lung. Particularly, these polymeric preparations were able to totally prevent migration of larvae to the mice brain.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app